Scientists propose that blocking a molecule that drives inflammation and organ damage in Gaucher, and maybe other lysosomal storage diseases, as a possible treatment with fewer risks and lower costs than current therapies. The team conducted the study in mouse models of lysosomal storage disease and in cells from blood samples donated by people with Gaucher disease.